Domov › Mnohonásobný myelóm › Kolumbijský okres › Washington
Klinické štúdie Mnohonásobný myelóm v meste Washington, DC
22 štúdií pre Mnohonásobný myelóm hľadá účastníkov v zariadeniach v meste Washington a okolí (do cca 30 míľ). Otvorte štúdiu a zistite, kto sa môže zapojiť a ako kontaktovať tím.
Oficiálny text štúdie (anglicky)
Hľadáte účastníkov do štúdie? Zvýraznite ju na začiatku tejto stránky – $99 na 30 dní →
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Prebieha náborFáza 1
- National Institutes of Health Clinical Center, Bethesda · 7 míľ odtiaľ
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Prebieha náborFáza 3
- Research Site, Washington D.C.
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Prebieha náborObservačná štúdia
- National Institutes of Health Clinical Center, Bethesda · 7 míľ odtiaľ
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Prebieha náborFáza 2
- National Institutes of Health Clinical Center, Bethesda · 7 míľ odtiaľ
Tissue Collection for Studies of Lymph Cancer
Prebieha náborObservačná štúdia
- National Institutes of Health Clinical Center, Bethesda · 7 míľ odtiaľ
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
Prebieha náborFáza 4
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda · 7 míľ odtiaľ
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Prebieha náborFáza 3
- Center for Cancer and Blood Disorders, Bethesda · 7 míľ odtiaľ
18F-Fluciclovine PET/CT in Multiple Myeloma
Prebieha náborFáza 2
- National Institutes of Health Clinical Center, Bethesda · 7 míľ odtiaľ
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Prebieha náborFáza 3
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda · 7 míľ odtiaľ
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
Prebieha náborFáza 2
- Lombardi Comprehensive Cancer Center, Washington D.C.
Collection of Tissue Samples for Cancer Research
Prebieha náborObservačná štúdia
- National Institutes of Health Clinical Center, Bethesda · 7 míľ odtiaľ
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Prebieha náborFáza 3
- Georgetown University Medical Center, Washington D.C.
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Prebieha náborFáza 3
- MedStar Washington Hospital Center MedStar Georgetown Cancer Institute, Washington D.C.
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
Prebieha náborFáza 2
- GSK Investigational Site, Bethesda · 7 míľ odtiaľ
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Prebieha náborFáza 3
- Sibley Memorial Hospital, Washington D.C.
Mosaic Trial for Stem Cell Transplant Recipients
Prebieha nábor
- Georgetown University School of Medicine, Washington D.C.
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Prebieha náborFáza 1
- Maryland Oncology Hematology - Silver Spring /ID# 268562, Silver Spring · 7 míľ odtiaľ
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Prebieha náborFáza 1/2
- The Center for Cancer and Blood Disorders (CCBD), Bethesda · 7 míľ odtiaľ
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Prebieha náborFáza 3
- Sibley Memorial Hospital, Washington D.C.
Cancer Experience Registry (CER) for Cancer Patients and Caregivers
Prebieha náborObservačná štúdiaVítaní zdravých dobrovoľníkov
- Cancer Support Community Research & Training Institute, Washington D.C.
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Prebieha náborFáza 3
- GSK Investigational Site, Washington D.C.
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Prebieha náborFáza 1/2
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
Štúdie Mnohonásobný myelóm v iných mestách
- New York City, NY60 štúdií
- Boston, MA42 štúdií
- Atlanta, GA42 štúdií
- Houston, TX38 štúdií
- Durham, NC37 štúdií
- Nashville, TN32 štúdií
- Denver, CO27 štúdií
- Rochester, MN24 štúdií
- St. Louis, MO24 štúdií
- Columbus, OH24 štúdií
- Baldwin Park, CA23 štúdií
- Edison, NJ22 štúdií
Iné štúdie v Washington
- Rakovina (všetky typy)58 štúdií
- Nemalobunkový karcinóm pľúc55 štúdií
- Rakovina prsníka46 štúdií
- Metastatická rakovina43 štúdií
- Rakovina pľúc41 štúdií
- Rakovina prostaty38 štúdií
- Obézita33 štúdií
- Kolorektálny karcinóm29 štúdií
- Kardiovaskulárne ochorenia28 štúdií
- Rakovina močového mechúra26 štúdií
- Akútna myeloidná leukémia24 štúdií
- Rakovina vaječníkov23 štúdií
Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.